CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 33 enrolled
Drug / intervention
Lopinavir/Ritonavir (Kaletra)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01153269
NCT01153269N/ACompleted
CompareCT.gov

Long-term Effectiveness and Safety in Hepatitis-co-infected Patients

Abbott·observational·Posted Jun 30, 2010·Updated Dec 19, 2011

In Brief

An observational study evaluating Lopinavir/Ritonavir (Kaletra) for Human Immunodeficiency Virus-Infection. Completed, enrolled 33 participants across 8 sites.

Detailed Summary

The aim of the study is to observe the tolerability and effectiveness of Kaletra in Human Immunodeficiency Virus/Hepatitis-B Virus and Human Immunodeficiency Virus/Hepatitis-C Virus co-infected patients.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHuman Immunodeficiency Virus-Infection
CountriesGermany
Collaborators--

Timeline

N/ACompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 30, 2010
Enrollment StartMay 1, 2001
Primary CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 9.5 yearsPosted 16.0 years ago

Interventions

Lopinavir/Ritonavir (Kaletra)drug

3 capsules 2xdaily or 2 tablets 2xdaily Kaletra